Clinical Trials Browser

Bone Marrow Failure Disorders, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Follicular, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Neoplasm, Residual, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Primary Myelofibrosis

NCT05820763 2024-07-10

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Phase 2 Withdrawn

Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT06158269 2023-12-06

DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

Phase 2 Recruiting

40 enrolled

Plasma cell

Multiple Myeloma, Neoplasm, Residual

Clinical Trials

EMAT

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

ROTATE

Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma